Cetuximab, a recombinant human-murine chimeric monoclonal antibody, binds explicitly to EGFR on the cell surface, internalizes it, and blocks the downstream signal transduction leading to inhibition of tumor cell proliferation, invasion, metastasis, angiogenesis, and promoting tumor cell apoptosis. This evidence concerns the gene EGFR and neoplasm.